Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126209861 | 12620986 | 1 | I | 20160720 | 20160804 | 20160804 | EXP | JP-ALVOGEN-2016-ALVOGEN-026997 | ALVOGEN | KAWAKAMI T, HIRABAYASHI Y, KAWAKAMI F, ISOBE R, KANEKO N, MIMURA Y ET AL. PERSISTENT INFECTION OF DRUG-RESISTANT INFLUENZA A VIRUS DURING CHEMOTHERAPY FOR MALIGNANT LYMPHOMA.INTERNAL MEDICINE. 2016; 55(13):1807-1810 | 80.00 | YR | M | Y | 0.00000 | 20160804 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126209861 | 12620986 | 1 | PS | DOXORUBICIN | DOXORUBICIN | 1 | (6 CYCLES) 6 COURSES | 65515 | |||||||||||
| 126209861 | 12620986 | 2 | SS | BENDAMUSTINE | BENDAMUSTINE | 1 | 2 COURSES | 0 | |||||||||||
| 126209861 | 12620986 | 3 | SS | PROCARBAZINE | PROCARBAZINE | 1 | 0 | /wk | |||||||||||
| 126209861 | 12620986 | 4 | SS | DEXAMETHASONE. | DEXAMETHASONE | 1 | (2 CYCLES) TWO COURSES | 0 | |||||||||||
| 126209861 | 12620986 | 5 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | EVERY OTHER DAY | 0 | 30 | MG | |||||||||
| 126209861 | 12620986 | 6 | SS | CISPLATIN. | CISPLATIN | 1 | (2 CYCLES) TWO COURSES | 0 | |||||||||||
| 126209861 | 12620986 | 7 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | (6 CYCLES) SIX COURSES | 0 | |||||||||||
| 126209861 | 12620986 | 8 | SS | VINCRISTINE | VINCRISTINE | 1 | (6 CYCLES) SIX COURSES | 0 | |||||||||||
| 126209861 | 12620986 | 9 | SS | GEMCITABINE | GEMCITABINEGEMCITABINE HYDROCHLORIDE | 1 | (2 CYCLES) TWO COURSES | 0 | |||||||||||
| 126209861 | 12620986 | 10 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | EVERY OTHER DAY | 0 | 50 | MG | |||||||||
| 126209861 | 12620986 | 11 | SS | RITUXIMAB | RITUXIMAB | 1 | (6 CYCLES) SIX COURSES | 0 | |||||||||||
| 126209861 | 12620986 | 12 | C | OSELTAMIVIR | OSELTAMIVIR | 1 | Oral | 0 | 75 | MG | BID | ||||||||
| 126209861 | 12620986 | 13 | C | PERAMIVIR | PERAMIVIR | 1 | Intravenous (not otherwise specified) | 0 | 300 | MG | |||||||||
| 126209861 | 12620986 | 14 | SS | PROCARBAZINE | PROCARBAZINE | 1 | EVERY OTHER DAY | 0 | 50 | MG | |||||||||
| 126209861 | 12620986 | 15 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | (6 CYCLES) SIX COURSES | 0 | |||||||||||
| 126209861 | 12620986 | 16 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | 0 | 30 | MG | ||||||||||
| 126209861 | 12620986 | 17 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | 0 | 20 | MG | ||||||||||
| 126209861 | 12620986 | 18 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | 0 | ||||||||||||
| 126209861 | 12620986 | 19 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | EVERY OTHER DAY | 0 | 50 | MG | |||||||||
| 126209861 | 12620986 | 20 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | 0 | ||||||||||||
| 126209861 | 12620986 | 21 | SS | RITUXIMAB | RITUXIMAB | 1 | (2 CYCLES) TWO COURSES | 0 | |||||||||||
| 126209861 | 12620986 | 22 | SS | RITUXIMAB | RITUXIMAB | 1 | (2 CYCLES) TWO COURSES | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126209861 | 12620986 | 1 | Lymphoma |
| 126209861 | 12620986 | 2 | Lymphoma |
| 126209861 | 12620986 | 3 | Lymphoma |
| 126209861 | 12620986 | 4 | Lymphoma |
| 126209861 | 12620986 | 5 | Lymphoma |
| 126209861 | 12620986 | 6 | Lymphoma |
| 126209861 | 12620986 | 7 | Lymphoma |
| 126209861 | 12620986 | 8 | Lymphoma |
| 126209861 | 12620986 | 9 | Lymphoma |
| 126209861 | 12620986 | 10 | Lymphoma |
| 126209861 | 12620986 | 11 | Lymphoma |
| 126209861 | 12620986 | 12 | Influenza |
| 126209861 | 12620986 | 13 | Influenza |
| 126209861 | 12620986 | 14 | Lymphoma |
| 126209861 | 12620986 | 15 | Lymphoma |
| 126209861 | 12620986 | 16 | Lymphoma |
| 126209861 | 12620986 | 17 | Lymphoma |
| 126209861 | 12620986 | 18 | Lymphoma |
| 126209861 | 12620986 | 19 | Lymphoma |
| 126209861 | 12620986 | 20 | Lymphoma |
| 126209861 | 12620986 | 21 | Lymphoma |
| 126209861 | 12620986 | 22 | Lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126209861 | 12620986 | HO |
| 126209861 | 12620986 | OT |
| 126209861 | 12620986 | DE |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126209861 | 12620986 | Influenza | |
| 126209861 | 12620986 | Therapeutic response decreased | |
| 126209861 | 12620986 | Viral load increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126209861 | 12620986 | 3 | 201502 | 0 | ||
| 126209861 | 12620986 | 5 | 201501 | 0 | ||
| 126209861 | 12620986 | 10 | 201501 | 0 | ||
| 126209861 | 12620986 | 12 | 201501 | 0 | ||
| 126209861 | 12620986 | 13 | 201502 | 0 | ||
| 126209861 | 12620986 | 14 | 201501 | 0 | ||
| 126209861 | 12620986 | 16 | 201412 | 0 | ||
| 126209861 | 12620986 | 18 | 201502 | 0 | ||
| 126209861 | 12620986 | 19 | 201501 | 0 | ||
| 126209861 | 12620986 | 20 | 201502 | 0 |